Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.1542
-0.0161 (-9.45%)
At close: Aug 14, 2026, 4:00 PM EDT
0.1556
+0.0014 (0.91%)
After-hours: Aug 14, 2026, 7:59 PM EDT
Gossamer Bio Revenue
Gossamer Bio had revenue of $9.24M in the quarter ending June 30, 2026, a decrease of -19.59%. This brings the company's revenue in the last twelve months to $53.29M, up 32.43% year-over-year. In the year 2025, Gossamer Bio had annual revenue of $48.47M, down -57.74%.
Revenue (ttm)
$53.29M
Revenue Growth
+32.43%
P/S Ratio
1.41
Revenue / Employee
$328,926
Employees
162
Market Cap
75.38M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.47M | -66.23M | -57.74% |
| Dec 31, 2024 | 114.70M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
GOSS News
- 1 day ago - Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 1 day ago - Gossamer Bio Quarterly report: Q2 2026 - Filings
- 1 day ago - Gossamer Bio Earnings release: Q2 2026 - Filings
- 18 days ago - Gossamer Bio upgraded to Outperform from Market Perform at Leerink - TheFly
- 18 days ago - Gossamer Bio Transcript: Investor update - Transcripts
- 18 days ago - Gossamer Bio Press release: Investor update - Filings
- 18 days ago - Gossamer announces FDA regulatory update, reacquisition of Seralutinib rights - TheFly
- 18 days ago - Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update - Business Wire